Targeting Heterogeneous Tumors Using a Multifunctional Molecular Prodrug

Area of Science:

• Biomedical Engineering
• Drug Delivery Systems
• Oncology

Background:

• Tumor microenvironments present challenges for drug delivery due to heterogeneity.
• Existing therapies often struggle with targeted drug release and efficacy in complex tumor conditions.

Purpose of the Study:

• To develop a molecular construct (K1) for targeted drug delivery in heterogeneous tumors.
• To investigate K1's ability to release an active drug (SN-38) in response to specific tumor microenvironment triggers.
• To evaluate K1's efficacy and toxicity in preclinical cancer models.

Main Methods:

• Design and synthesis of the K1 molecular construct.
• In vitro studies assessing prodrug activation by glutathione (GSH) and hydrogen peroxide (H2O2).
• Evaluation of K1 uptake and anticancer activity in colon cancer cell lines (SW620, LoVo).
• In vivo studies using a xenograft tumor regrowth model to assess therapeutic efficacy and toxicity.

Main Results:

• K1 demonstrated environmentally triggered release of SN-38 under oxidative and reductive stress.
• Specific uptake of K1 was observed in COX-2 positive colon cancer cells.
• K1 exhibited enhanced anticancer activity and downregulated key cancer survival pathways (AKT, p38, IL-6, VEGF, TNF-α).
• K1 showed improved in vivo therapeutic efficacy with no significant systemic toxicity.

Conclusions:

• The K1 construct offers a promising strategy for overcoming drug delivery challenges in heterogeneous solid tumors.
• Environmentally triggered drug release and simultaneous redox stress scavenging contribute to K1's enhanced efficacy.
• K1 presents a potential therapeutic approach for aggressive colon cancers and other solid tumors.